Solubilization, Hansen solubility parameters and apparent thermodynamic parameters of Osimertinib in (propylene glycol + water) cosolvent mixtures
Author:
Shakeel Faiyaz1, Anwer Md. Khalid2, Haq Nazrul1, Alsarra Ibrahim A.1
Affiliation:
1. Department of Pharmaceutics , College of Pharmacy, King Saud University , Riyadh , Saudi Arabia 2. Department of Pharmaceutics , College of Pharmacy, Prince Sattam Bin Abdulaziz University , Al-Kharj , Saudi Arabia
Abstract
Abstract
The solubilization, Hansen solubility parameters (HSPs) and apparent thermodynamic parameters of a novel anticancer medicine osimertinib (OMT) in binary propylene glycol (P) + water (W) cosolvent mixtures were evaluated. The mole fraction solubility (x
e) of OMT in various (P + W) cosolvent mixtures including neat P and neat W was determined at T = 298.2–318.2 K and p = 0.1 MPa by applying a saturation shake flask method. HSPs of OMT, neat P, neat W and (P + W) cosolvent compositions free of OMT were also estimated. The x
e values of OMT were regressed with Van’t Hoff, modified Apelblat, Yalkowsky-Roseman, Jouyban-Acree and Jouyban-Acree-Van’t Hoff models with an average errors of <3.0 %. The highest and lowest x
e value of OMT was estimated in neat P (2.70 × 10−3 at T = 318.2 K) and neat W (1.81 × 10−5 at T = 298.2 K), respectively. Moreover, HSP of OMT was found to be closed with that of neat P. The solubility of OMT was found to be increased significantly with an increase in temperature and P mass fraction in all (P + W) cosolvent compositions including neat P and neat W. The results of activity coefficients suggested higher molecular interactions in OMT-P combination compared with OMT-W combination. The results of thermodynamic studies indicated an endothermic and entropy-driven dissolution of OMT in all (P + W) cosolvent compositions including neat P and neat W.
Publisher
Walter de Gruyter GmbH
Subject
Physical and Theoretical Chemistry
Reference38 articles.
1. US FDA. AstraZeneca Pharmaceuticals LP TAGRISSOTM (osimertinib) tablet: highlights of prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s007lbl.pdfN (accessed Jan 29, 2018). 2. Herbst, R. S., Heymach, J. V., Lippman, S. M. N. Engl. J. Med. 2008, 359, 1367; https://doi.org/10.1056/nejmra0802714. 3. Yang, P., Allens, M. S., Abury, M. C., Wampfler, J. A., Marks, R. S., Thibodeau, S., Adiei, A. A., Jett, J., Deschamps, C. Chest 2005, 128, 452; https://doi.org/10.1378/chest.128.1.452. 4. Castro, A. S., Parente, B., Gonçalves, I., Antunes, A., Barroso, A., Conde, S., Neves, S., Machado, J. C. Rev. Port. Pneumol. 2013, 19, 7; https://doi.org/10.1016/j.rppnen.2013.01.002. 5. Gahr, S., Stoehr, R., Geissinger, E., Ficker, J. H., Brueckl, W. M., Gschwendtner, A., Gattenloehner, S., Fuchs, F. S., Schulz, C., Rieker, R. J., Hartmann, A., Ruemmele, P., Dietmaier, W. Br. J. Cancer 2013, 109, 1821; https://doi.org/10.1038/bjc.2013.511.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|